- About the Fund
- Our Work With States
- The Milbank Quarterly
- Newsletter & Updates
The Milbank Memorial Fund is an endowed operating foundation that works to improve the health of populations by connecting leaders and decision makers with the best available evidence and experience.
Learn about the MMF
July 5, 2016
A new financial simulation for a novel model of care, called MediCaring Communities, has shown significant Medicare savings for frail older adults who need both medical care and nonmedical support services. In a new Early View Milbank Quarterly study, Joanne Lynn, director of Altarum Institute’s Center for Elder Care and Advanced Illness, and colleagues, found that the United States could provide much better care for disabled and sick elderly people without exceeding what we now spend.
June 24, 2016
As the end of the month approaches, so does the end of phase one of SMART-D, the State Medicaid Alternative Reimbursement and Purchasing Test for High-Cost Drugs. A project of the Center for Evidence-based Policy (CEbP) at Oregon Health and Science University, SMART-D is part of a series of grants from the Laura and John Arnold Foundation in Houston, Texas, that address the rising cost of pharmaceutical drugs. SMART-D is aimed at developing a better menu of options for states to consider in purchasing high-cost drugs in Medicaid.
June 8, 2016
It is projected that by 2050, 83.7 million Americans will be over the age of 65, almost double the number who were that age in 2012. During its fall 2015 meetings, the Milbank Memorial Fund’s Reforming States Group turned its attention to the topic, partnering with The New York Academy of Medicine to develop sessions focused on some of the major challenges and opportunities facing states as they look at ways to support an aging population.
The new report, “How Can States Support an Aging Population? Actions Policymakers Can Take,” by Lindsay Goldman and Robert Wolf of the New York Academy of Medicine, provides a review of the issues discussed at the meetings, as well as recommendations for state policy interventions.
||Read more news|
Christopher F. Koller
President of the
Milbank Memorial Fund
With threats of lawsuits and pressure from government officials, some payers appear to be relaxing their coverage guidelines for expensive direct-acting antiviral drugs (DAAs), including drugs for Hepatitis C. The benefits that increased access to these drugs provide to patients with Hepatitis C—and to the drugs’ manufacturers and investors—will come at the expense of state budgets and, more importantly, broader discussions about matching demand for health care services to limited resources.